Free Trial

InMode (INMD) Stock Forecast & Price Target

InMode logo
$17.08 -0.11 (-0.64%)
(As of 12/20/2024 05:40 PM ET)

InMode - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
2

Based on 6 Wall Street analysts who have issued ratings for InMode in the last 12 months, the stock has a consensus rating of "Hold." Out of the 6 analysts, 4 have given a hold rating, and 2 have given a buy rating for INMD.

Consensus Price Target

$22.60
32.32% Upside
According to the 6 analysts' twelve-month price targets for InMode, the average price target is $22.60. The highest price target for INMD is $27.00, while the lowest price target for INMD is $16.00. The average price target represents a forecasted upside of 32.32% from the current price of $17.08.
Get the Latest News and Ratings for INMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for InMode and its competitors.

Sign Up

INMD Analyst Ratings Over Time

TypeCurrent Forecast
12/22/23 to 12/21/24
1 Month Ago
11/22/23 to 11/21/24
3 Months Ago
9/23/23 to 9/22/24
1 Year Ago
12/22/22 to 12/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$22.60$22.60$22.40$40.50
Forecasted Upside32.32% Upside22.26% Upside28.59% Upside78.26% Upside
Consensus Rating
Hold
Hold
Hold
Hold

INMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

INMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

InMode Stock vs. The Competition

TypeInModeMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.81
2.51
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside32.32% Upside25,828.59% Upside14.52% Upside
News Sentiment Rating
Positive News

See Recent INMD News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/31/2024Needham & Company LLC
2 of 5 stars
 Reiterated RatingHold
10/17/2024BTIG Research
2 of 5 stars
M. Thibault
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$25.00+48.10%
10/14/2024Barclays
3 of 5 stars
 Lower TargetOverweight ➝ Overweight$29.00 ➝ $27.00+63.44%
7/23/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$21.00 ➝ $19.00+7.04%
7/12/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$21.00 ➝ $16.00-8.94%
2/14/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$24.00 ➝ $26.00+13.49%
Why I'm telling friends to avoid gold stocks (Ad)

Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."

And if you’d like to get your hands on this, here you go, the complete breakdown.
7/28/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform$53.00 ➝ $61.00+38.45%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:50 PM ET.


INMD Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for InMode is $22.60, with a high forecast of $27.00 and a low forecast of $16.00.

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for InMode in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" INMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INMD, but not buy additional shares or sell existing shares.

According to analysts, InMode's stock has a predicted upside of 32.32% based on their 12-month stock forecasts.

InMode has been rated by research analysts at Barclays, BTIG Research, and Needham & Company LLC in the past 90 days.

Analysts like InMode less than other "medical" companies. The consensus rating for InMode is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how INMD compares to other companies.


This page (NASDAQ:INMD) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners